Inspira Technologies to Debut HYLA™ Blood Sensor
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN), based in Israel, is excited to announce the debut of its HYLA™ blood sensor technology at an upcoming prestigious medical conference. This groundbreaking product will be showcased to healthcare professionals during the ELSO Annual Conference, an event that occurs from September 27 to September 30. Such a platform is noted for being significant within the realm of extracorporeal life support (ECLS).
Impressive Performance Data of HYLA
This unveiling follows Inspira Technologies' recent confirmation of the HYLA sensor's remarkable accuracy, achieving an impressive 97.35% accuracy rate when compared to traditional blood gas analyzers. The precision of this innovative device positions it as a vital tool for medical professionals in critical care settings.
The Importance of ELSO Conference
The ELSO conference, recognized globally, enables thousands of leading clinicians, researchers, and industry experts to explore the latest developments in medical technology. It provides an unparalleled opportunity for Inspira Technologies to not only unveil the HYLA sensor but also to engage with thought leaders and decision-makers in the field of medical devices.
Strategic Partnerships and Commercialization
In addition to the presentation, Executives from Inspira Technologies will hold strategic discussions with top-tier medical device companies and hospital networks. These meetings aim to cultivate potential partnerships and commercialization pathways that could enhance the reach and impact of the HYLA platform in healthcare.
Statements from Leadership
Dagi Ben-Noon, CEO of Inspira Technologies, expressed enthusiasm about this upcoming milestone: "After years of dedicated development, we're thrilled to present the HYLA sensor on such a grand stage. This is not just about showcasing its accuracy; it's about influencing future standards of care through engagement with key industry partners. We're committed to making this technology a standard tool in the industry, ultimately empowering clinicians to improve patient outcomes."
Other Innovations at the Conference
At the same conference, Inspira Technologies will also present its FDA-cleared ART100 system, which emphasizes the company’s focus on advanced life-support solutions. This existing platform underlines Inspira's commitment to providing comprehensive and effective medical solutions, significantly addressing critical care needs.
About Inspira Technologies
Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions. Their US FDA-cleared INSPIRA™ ART100 system is already approved for use in cardiopulmonary bypass procedures within the United States, and their next-generation INSPIRA ART500 system is under development, aiming to enhance patient experience further. The commitment to non-invasive monitoring through the HYLA™ blood sensor illustrates their focus on innovative developments that align with modern medical needs.
Frequently Asked Questions
What is HYLA™?
HYLA is a groundbreaking blood sensor technology that provides real-time, non-invasive blood monitoring with high accuracy rates.
Where will the HYLA™ blood sensor be showcased?
The HYLA blood sensor will be unveiled at the ELSO Annual Conference in Washington, D.C.
What is Inspira Technologies known for?
Inspira Technologies is recognized for its innovative life-support and diagnostic medical technologies, including advanced respiratory support systems.
What performance data supports HYLA's effectiveness?
The HYLA sensor has demonstrated a remarkable 97.35% accuracy rate compared to traditional blood gas analyzers, showcasing its reliability.
How does Inspira Technologies contribute to patient care?
By developing advanced medical devices such as HYLA and ART100, Inspira Technologies aims to enhance clinical decision-making and patient outcomes.
